Mycobacterium Patents (Class 435/253.1)
-
Patent number: 7579141Abstract: The invention provides polypeptides encoded by open reading frames present in the genome of Mycobacterium tuberculosis but absent from the genome of BCG and diagnostic and prophylactic methodologies using these polypeptides.Type: GrantFiled: February 21, 2007Date of Patent: August 25, 2009Assignee: University of Medicine and Dentistry of New JerseyInventor: Maria Laura Gennaro
-
Patent number: 7575862Abstract: The present invention relates to an assay system, kits and methods for detecting microorgansims (especially for M. tuberculosis) of suspected patient. The present invention also relates to an apparatus for performing the integration of thermal and magnetic control in the same apparatus to largely reduce the whole process of M. tuberculosis detection is less than 5 hours.Type: GrantFiled: December 9, 2003Date of Patent: August 18, 2009Assignee: AsiaGen CorporationInventors: George Chin-Sheng Chou, Chang-Yi Huang
-
Patent number: 7547506Abstract: The present invention provides an assay for detection of M. bovis-infected animals. A tracer, comprising a peptide of M. bovis protein MPB70 conjugated to a fluorophore, is added to a serum sample from an animal to form a mixture. The fluorescence polarization of the mixture in then measured and compared to the fluorescence polarization of a control. The present invention further provides a tracer for use in fluorescence polarization assay to detect antibodies specific for M. bovis. The tracer comprises a peptide of M. bovis protein MPB70 conjugated to a fluorophore, such that the tracer is able to bind to antibodies specific for M. bovis to produce a detectable change in fluorescence polarization.Type: GrantFiled: October 31, 2002Date of Patent: June 16, 2009Assignees: Diachemix LLC, Her Majesty the Queen in Right of Canada, as represented by the Canadian Food Inspection AgencyInventors: Om P. Surujballi, Anna Romanowska, Michael E. Jolley, Mohammad Sarwar Nasir
-
Patent number: 7538206Abstract: The present invention is directed to a method of selection of purified nucleotidic sequences or polynucleotides encoding proteins or part of proteins carrying at least an essential function for the survival or the virulence of mycobacterium species by a comparative genomic analysis of the sequence of the genome of M. tuberculosis aligned on the genome sequence of M. leprae and M. tuberculosis and M. leprae marker polypeptides of nucleotides encoding the polypeptides, and methods for using the nucleotides and the encoded polypeptides are disclosed.Type: GrantFiled: February 22, 2002Date of Patent: May 26, 2009Assignee: Institut PasteurInventor: Stewart Cole
-
Patent number: 7521040Abstract: An immunotherapy useful for treating a cancer and/or treating and preventing a microbial infection is provided. A pharmaceutical composition which comprises a bacterial component as an effective ingredient is disclosed, which is used for immunotherapy in a patient suffering from a cancer or microbial infection, wherein the immunotherapy comprises eradicating the cancer cells or the microorganisms from the lymph nodes of the patient.Type: GrantFiled: March 19, 2007Date of Patent: April 21, 2009Inventor: Akira Hayashi
-
Publication number: 20090082296Abstract: A method is provided for identifying mycobacterial genes that are induced or up-regulated under culture conditions that are nutrient-starving and which maintain mycobacterial latency, said conditions being obtainable by batch fermentation of a mycobacterium for at least 20 days post-inoculation, when compared with culture conditions that are not nutrient-starving and which support exponential growth of said mycobacterium. Said induced or up-regulated genes form the basis of nucleic acid vaccines, or provide targets to allow preparation of attenuated mycobacteria for vaccines against mycobacterial infections. Similarly, peptides encoded by said induced or up-regulated genes are employed in vaccines. In a further embodiment, the identified genes/peptides provide the means for identifying the presence of a mycobacterial infection in a clinical sample by nucleic acid probe or antibody detection.Type: ApplicationFiled: June 16, 2008Publication date: March 26, 2009Inventors: Brian W. James, Philip Marsh, Tobias Hampshire
-
Publication number: 20090068231Abstract: The present invention provides live, attenuated Mycoplasma bacteria that exhibit reduced expression of one or more proteins selected from the group consisting of pyruvate dehydrogenase, phosphopyruvate hydratase, 2-deoxyribose-5-phosphate aldolase, and ribosomal protein L35, relative to a wild-type Mycoplasma bacterium of the same species. Also provided are vaccines and vaccination methods involving the use of the live, attenuated Mycoplasma bacteria, and methods for making live attenuated Mycoplasma bacteria.Type: ApplicationFiled: September 10, 2008Publication date: March 12, 2009Applicant: WyethInventors: Mahesh Kumar, Muhammad Ayub Khan
-
Publication number: 20090023596Abstract: A method of inducing latency in Mycobacterium permits preparation of an in vitro model system of latent mycobacterial infection. Latency is induced in a pure culture of Mycobacterium by exposing it to multiple stress conditions, including a low nutrient culture medium without glycerol, a low pH, a relatively high level of carbon dioxide and a relatively low gas phase oxygen level. An in vitro model of mycobacterial infection employs macrophages induced from THP1 cells which are then infected with Mycobacterium. The infected macrophages are grown under hypoxic conditions to induce latency in the mycobacteria. The in vitro model of infection is useful in evaluating compounds for activity against latent mycobacteria.Type: ApplicationFiled: April 22, 2008Publication date: January 22, 2009Inventors: Pappachan Kolattukudy, Tatiana Sirakova, Jaiyanth Daniel, Chirajyoti Deb
-
Publication number: 20090017061Abstract: The present invention relates to mycobacterial lipoarabinomannan cap-specific mannosyl transferases and nucleic acid encoding such transferases. The invention further relates to Mycobacteria in which the lipoarabinomannan cap-specific mannosyl transferases have been inactivated and that therefore express mannose cap-deficient lipoarabinomannan. Such Mycobacteria with mannose cap-deficient lipoarabinomannan may be used as more effective vaccines against mycobacterial diseases as they lack the immunosuppressive action of the mannose cap.Type: ApplicationFiled: January 18, 2006Publication date: January 15, 2009Inventors: Bernard Jan Appelmelk, Wilhelmus Bitter, Peter Andre van der Ley
-
Patent number: 7476391Abstract: Gram negative bacterial virulence genes are identified, thereby allowing the identification of novel anti-bacterial agents that target these virulence genes and their products, and the provision of novel gram negative bacterial mutants useful in vaccines.Type: GrantFiled: May 26, 2004Date of Patent: January 13, 2009Assignee: Pharmacia & Upjohn CompanyInventors: David E. Lowery, Troy E. Fuller, Michael J. Kennedy
-
Patent number: 7452721Abstract: Methods for the diagnosis of visceral, cutaneous and canine leishmaniasis in a subject suspected of being infected with the parasitic protozoa Leishmania is disclosed. Disclosed are antibody-capture enzyme-linked immunosorbent assays (ELISAs) for the detection of antibodies to Leishmania parasite soluble antigens and antigen-capture ELISAs for the detection of Leishmania parasite soluble antigens in host samples. Also disclosed are immunodiagnostic kits for the detection of Leishmania parasite circulating antigens or IgM and IgG antibodies in a sample from subject having visceral, cutaneous or canine leishmaniasis. In these methods and kits, detection may be done photometrically or visually. The methods and kits also allow the visualization of Leishmania amastigotes or promastigotes in a sample.Type: GrantFiled: November 18, 2004Date of Patent: November 18, 2008Assignee: The United States of America as represented by the Secretary of the ArmyInventor: Samuel K. Martin
-
Patent number: 7445915Abstract: The present invention provides a polypeptide comprising an amino acid sequence in which at least one amino acid is deleted, substituted or added in an amino acid sequence of isopropylmalate isomerase derived from a microorganism belonging to coryneform bacteria, wherein a coryneform bacterium which produces the polypeptide comprising the amino acid sequence as the sole isopropylmalate isomerase exhibits a partial leucine requirement in a minimal medium; a DNA encoding the polypeptide, a recombinant DNA comprising the DNA, a microorganism transformed with the recombinant DNA, and a process for producing an L-amino acid using the microorganism.Type: GrantFiled: March 19, 2003Date of Patent: November 4, 2008Assignee: Kyowa Hakko Kogyo Co., Ltd.Inventors: Masato Ikeda, Mikiro Hayashi, Junko Ohnishi, Satoshi Mitsuhashi, Hiroshi Mizoguchi, Satoshi Nakagawa
-
Patent number: 7445895Abstract: The present invention relates to methods, kits and assay system for detecting drug-resistant Mycobacterium tuberculosis of suspected patient. The system of the present invention largely reduces the whole process of drug-resistant Mycobacterium tuberculosis detection to less than 5 hours.Type: GrantFiled: April 28, 2004Date of Patent: November 4, 2008Assignee: AsiaGEN CorporationInventors: George Chin-Sheng Chou, Chuang-Yi Huang
-
Publication number: 20080260769Abstract: A system for expressing antigenic polypeptides in oligomeric form fuses the antigenic polypeptide to an oligomerisation polypeptide such that the oligomerisation polypeptide can interact with other oligomerisation polypeptides and bring multiple copies of the antigenic polypeptide into close proximity in the form of an oligomer. Expressing the polypeptides in oligomeric form in this way can improve their immunogenicity compared to a monomeric form.Type: ApplicationFiled: July 22, 2005Publication date: October 23, 2008Inventors: Barbara Capecchi, Vega Masignani, Rino Rappuoli, Maria Scarselli
-
Publication number: 20080254061Abstract: Provided are recombinant mycobacteria expressing an HIV-1 antigen and a malarial antigen. Also provided are Mycobacterium smegmatis expressing an HIV-1 antigen. Further provided are vaccines capable of inducing an immune response in a mammal against HIV-1 and the malarial pathogen. Additionally provided are methods of inducing an immune response in a mammal against HIV-1 and a malarial pathogen. Also provided are methods of inducing an immune response in a mammal against HIV-1. The methods comprise infecting the mammal with any of the above-described mycobacteria.Type: ApplicationFiled: January 11, 2006Publication date: October 16, 2008Inventors: William R. Jacobs, Norman L. Letvin, Mark Cayabyab, Barton F. Haynes, Hua-Xin Liao, Jae-Sung Yu, Avi-Hai Hovav
-
Publication number: 20080242676Abstract: Novel pyrrole derivatives of formula (I) and their pharmaceutically acceptable acid addition salts having superior antimycobacterial activity against clinically sensitive as well as resistant strains of Mycobacterium tuberculosis as well as having lesser toxicity compared to known compounds. The use of the novel compounds of formula (I) for treatment of latent tuberculosis including Multi Drug Resistant Tuberculosis (MDR TB). The methods for preparation of the novel compounds, pharmaceutical compositions containing the novel compounds and method of treating MDR TB by administration of compounds of formula (I).Type: ApplicationFiled: June 11, 2008Publication date: October 2, 2008Applicant: Lupin LimitedInventors: Sudershan Kumar Arora, Neelima Sinha, Sanjay Jain, Ram Shankar Upadhayaya, Gourhari Jana, Shankar Ajay, Rakesh Kumar Sinha
-
Patent number: 7393541Abstract: Compositions and methods for enhancing the immunity of a subject or vaccinating a subject against mycobacterial infections are disclosed. The invention provides compositions comprising formalin inactivated cultures of a mycobacterium, such as M. bovis, and a Novasome® adjuvant, as well as methods for using such compositions.Type: GrantFiled: May 13, 2004Date of Patent: July 1, 2008Assignee: Novavax, Inc.Inventors: D. Craig Wright, Joan Brisker, Mark A. Chambers
-
Publication number: 20080138840Abstract: A method of detecting an immune response to a paratuberculosis-specific antigen, comprising incubating a sample from a subject with the paratuberculosis-specific antigen and detecting the presence of an antibody in the sample as an indication of an immune response to the paratuberculosis-specific antigen. The antigen may be obtained from a novel M. paratuberculosis strain JTC303. The antigen may be obtained from the JTC303 culture filtrate. Also provided are antibodies to the paratuberculosis-specific antigen, and a diagnostic kit for the detection of an immune response to a paratuberculosis-specific antigen in a mammal.Type: ApplicationFiled: September 5, 2007Publication date: June 12, 2008Inventors: Michael T. Collins, Sung Jae Shin, Donghee Cho
-
Publication number: 20080131458Abstract: The invention relates to a novel adjuvant Mycobacterium w and or its constituents and adjuvant containing composition, which contains antigen (s) with pharmaceutical acceptable carrier and its uses. Mycobacterium w and or its constituents when administered with antigen (s) to mammal results in enhanced immunogenicity of antigen. The enhanced immunogenicity manifests as humoral responses as well as cell mediated immunity. The adjuvant effect is seen with variety of antigens in various mammals irrespective of their immune status at the time of administration of Mycobacterium w and antigen containing composition. e.g. immune naïve or preimmunised status.Type: ApplicationFiled: April 21, 2006Publication date: June 5, 2008Applicant: Cadila Pharmaceuticals Ltd.Inventors: Bakulesh Mafatlal Khamar, Rajiv Indravadan Modi, Indravadan Arnbalal Modi, Prasanta Kumar Ghosh, Nirav Desai
-
Patent number: 7371842Abstract: It is intended to provide a protein participating in the regulation of sugar production, a polynucleotide encoding the same, a method of screening a compound participating in the regulation of sugar production and a drug for treating or preventing diabetes which contains the compound participating in the regulation of sugar production. A polynucleotide encoding a protein specifically binding to a substance WF00144 is found out from rat liver cells and thus a protein participating in the regulation of sugar production and a polynucleotide encoding the same are provided. Moreover, a method and a substance relating to a method of treating and preventing diabetes are found out and thus a method of treating diabetes relating to the regulation of sugar production relating to the method of treating and preventing diabetes is provided.Type: GrantFiled: April 28, 2003Date of Patent: May 13, 2008Assignee: Astellas Pharma Inc.Inventors: Hidenori Nakajima, Mitsuru Ohkubo, Seiji Yoshimura, Nobuya Nishio, Kaori Nishio
-
Patent number: 7371571Abstract: Recombinant mycobacterial strains which overproduce essential biosynthetic enzymes of pathogenic mycobateria are provided. These strains overproduce enzymes involved in the synthesis and incorporation of D-alanine into mycobacterial peptidoglycan, the backbone of the mycobacterial cell wall. These overproducing strains may be used as reference strains in in vitro screening methods to identify antimycobacterial agents.Type: GrantFiled: December 17, 2003Date of Patent: May 13, 2008Assignee: Board of Regents University of Nebraska - LincolnInventors: Raul G. Barletta, Zhengyu Feng
-
Patent number: 7364740Abstract: Specific genetic deletion are identified in mycobacteria isolates, including variations in the M. tuberculosis genome sequence between isolates, and numerous deletion present in BCG as compared to M. tb. These deletions are used as markers to distinguish between pathogenic and avirulent strains, and as a marker for particular M. tb isolates. Deletions specific to vaccine strains of BCG are useful in determining whether a positive tuberculin skin test is indicative of actual tuberculosis infection. The deleted sequences may be re-introduced into BCG to improve the efficacy of vaccination. Alternatively, the genetic sequence that corresponds to the deletion(s) are deleted from M. bovis or M. tuberculosis to attenuate the pathogenic bacteria.Type: GrantFiled: June 1, 2005Date of Patent: April 29, 2008Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Marcel Behr, Peter Small, Gary Schoolnik, Michael A. Wilson
-
Patent number: 7364856Abstract: The present invention relates to a pknB kinase and a pstP phosphatase as well as their use for identifying antibacterial substances.Type: GrantFiled: August 3, 2005Date of Patent: April 29, 2008Assignee: Institut PasteurInventors: Pedro Alzari, Brigitte Boitel, Andrea Villarino, Pablo Fernandez, Steward T. Cole
-
Publication number: 20080050795Abstract: A mixture of isolated or synthetic affinity molecules in a liquid carrier is disclosed. The mixture comprises at least two different affinity molecules, each with affinity for a predetermined analyte, for use in a single or multi flow cell piezoelectric crystal micro balance apparatus. Each isolated or synthetic affinity molecule forms together with the predetermined analyte an interaction pair selected from the group consisting of anion-cation, antibody-antigen, receptor-ligand, enzyme-substrate, oligonucleotide-oligonucleotide with complementary sequence, oligonucleotide-protein, oligonucleotide-cell, and peptide nucleic acid (PNA) oligomer-polynucleotide, wherein the polynucleotide may be selected from the group consisting of RNA, DNA and PNA polymers complementary to PNA oligomer. Use of the mixture for introduction into the liquid flow of a single or multi flow cell piezoelectric crystal micro balance apparatus is also described, as well as a kit containing the mixture.Type: ApplicationFiled: November 19, 2004Publication date: February 28, 2008Applicant: Biosensor Applications Sweden ABInventors: Per Mansson, Daniel Berggren, Carl Lundberg, Ann-Charlotte Hellgren, Lena Hojvall
-
Patent number: 7288261Abstract: Vaccine compositions for boosting immunity to mycobacteria when administered in mid-life in a subject who has been vaccinated neonatally or in early childhood with BCG and in whom protective immunity has waned comprise one or more purified immunogenic proteins from Mycobacterium tuberculosis from a group of 30 proteins that stimulate T cell immunity and interferon-? secretion. A preferred protein is Ag85A, the secreted product (SEQ ID NO:31) of the Rv3084c gene. Also disclosed are methods for boosting immunity in such BCG-vaccinated subjects comprising administering an effective amount of the above vaccine composition.Type: GrantFiled: July 10, 2001Date of Patent: October 30, 2007Assignee: Colorado State University Research FoundationInventors: Ian M. Orme, John T. Belisle
-
Patent number: 7273602Abstract: An immunotherapy useful for treating a cancer and/or treating and preventing a microbial infection is provided. A pharmaceutical composition which comprises a bacterial component as an effective ingredient is disclosed, which is used for immunotherapy in a patient suffering from a cancer or microbial infection, wherein the immunotherapy comprises eradicating the cancer cells or the microorganisms from the lymph nodes of the patient.Type: GrantFiled: July 19, 2002Date of Patent: September 25, 2007Inventor: Akira Hayashi
-
Patent number: 7264815Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: GrantFiled: January 4, 2006Date of Patent: September 4, 2007Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 7259005Abstract: Disclosed is a microorganism having an excellent ability to convert sterol into and rost-4-ene-3,17-dione (AD) and androsta-1,4-diene-3,17-dione (ADD), a method for preparation of the microorganism and use thereof, and more particularly, a mutant strain of Mycobacterium fortuitum ATCC 29472, Mycobacterium fortuitum EUG-119, a method for preparation of the mutant and use thereof in preparing AD and ADD. The mutant of the present invention has an excellent ability to convent sterol into AD and ADD which are steroid hormone precursors, compared with the known microorganisms and accordingly, is very useful for mass production of steroid hormones.Type: GrantFiled: May 10, 2002Date of Patent: August 21, 2007Assignee: Eugene Science Inc.Inventors: Seung-Kwon Noh, Myung-Kuk Kim, Won-Tae Yoon, Kyung-Moon Park, Sang-Ok Park
-
Patent number: 7247430Abstract: The present invention pertains to polynucleotides derived from M. tuberculosis genes imparting resistance to antibiotics and chemically related compounds. This invention also relates to the use of the polynucleotides as oligonucleotide primers or probes for detecting M. tuberculosis strains that are resistant to antibiotics and related compounds in a biological sample. Kits containing the primers and probes are also provided.Type: GrantFiled: August 13, 2002Date of Patent: July 24, 2007Assignee: Institut PasteurInventor: Brigitte Gicquel
-
Patent number: 7244613Abstract: The invention concerns recombinant vectors replicated in mycobacteria, a set of sequences coding for exported polypeptides detected by fusion with alkaline phosphatase, in particular one polypeptide, called DP428, of about 12 kD corresponding to an exported protein found in mycobacteria belonging to the Mycobacterium tuberculosis complex. The invention also concerns methods and kits for detecting in vitro the presence of a mycobacterium and in particular a mycobacterium belonging to the Mycobacterium tuberculosis complex in a biological sample using said polypeptides, their fragments or polynucleotides coding for the latter. The invention also concerns immunogenic or vaccine compositions for preventing and/or treating infections caused by mycobacteria and in particular a mycobacterium belonging to said complex, particularly tuberculosis.Type: GrantFiled: May 16, 2001Date of Patent: July 17, 2007Assignee: Institut PasteurInventors: Brigitte Gicquel, Denis Portnoï, Eng-Mong Lim, Vladimir Pelicic, Agnès Guigueno, Yves Goguet De La Salmoniere
-
Patent number: 7241589Abstract: The present invention relates to a method for preparation of androst-4-ene-3,17-dione (AD) and androsta-1,4-diene-3,17-dione (ADD). More particularly, the present invention relates to a method for preparing AD/ADD, comprising the steps of: (a) heating sterols and emulsifier respectively, to dissolve completely and mixing to prepare a mixture; (b) placing the mixture in a water bath at 70˜90° C. and stirring to obtain emulsified sterols; and (c) adding the emulsified sterols to culture media of microorganism as a component. And the present invention relates to a method for preparing AD/ADD, comprising the addition of cyclodextrin-sterol complexes extracted from milk to culture media of microorganism as a component. The emulsified sterols and cyclodextrin-sterol complexes adopted in the present invention can be easily prepared and be effectively used for obtaining AD/ADD at a high yield.Type: GrantFiled: May 10, 2002Date of Patent: July 10, 2007Assignee: Eugene Science Inc.Inventors: Seung-Kwon Noh, Myung-Kuk Kim, Won-Tae Yoon, Kyung-Moon Park, Sang-Ok Park
-
Patent number: 7238358Abstract: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.Type: GrantFiled: January 3, 2005Date of Patent: July 3, 2007Assignee: Corixa CorporationInventors: Steven G. Reed, Yasir A. W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik, Michael J. Lodes, Ronald C. Hendrickson
-
Patent number: 7166457Abstract: A process for the treatment of aqueous effluents containing at least one of the following ethers is described: ethyl tert-butyl ether (ETBE) and/or methyl tert-butyl ether (MTBE) and/or tert-amyl methyl ether (TAME) in order to reduce the concentration of these ethers. A bacterium Gordonia terrae CIP I-2194 is innoculated under aerobic conditions. In particular, a bacterium Burkholderia cepacia CIP I-2052 or a bacterium Alcaligenes sp. CIP I-2561 or a bacterium Mycobacterium sp. CIP I-2562 is added in the presence of a growth substrate and, optionally, of a cobalt salt, and the ether contained in the effluents is degraded by the bacteria thus innoculated until its mineralization. The process is useable in the ether-contaminated water treatment industry.Type: GrantFiled: November 9, 2000Date of Patent: January 23, 2007Assignee: Institut Fracois du PetroleInventors: Guillermina Hernandez, Alan Francois, Pascal Piveteau, Francoise Fayolle, Frederic Monot
-
Patent number: 7163819Abstract: Genes encoding bacterial oxygen binding proteins are provided. Recombinant expression of at least one of the present bacterial hemoglobin genes increased the growth characteristics and/or carotenoid production levels in microbial host cells grown under microaerobic conditions.Type: GrantFiled: April 4, 2006Date of Patent: January 16, 2007Assignee: E. I. du Pont de Nemours and CompanyInventors: Qiong Cheng, Michael P. Perry, Luan Tao
-
Patent number: 7135280Abstract: Method of determining the efficacy of treatment for mycobacterial infection in an individual comprising determining in samples from the individual whether the level of T cells specific for a mycobacterial antigen has decreased after the treatment, thereby determining the efficacy of the treatment.Type: GrantFiled: January 8, 2002Date of Patent: November 14, 2006Assignee: Isis Innovation LimitedInventor: Ajit Lalvani
-
Patent number: 7125858Abstract: The present invention relates to a composition and method comprising purified HA, a second anti-neoplastic agent and a pharmaceutically acceptable carrier, wherein the purified HA and the second anti-neoplastic agent are administered to a mammal having cancer in an amount effective to treat the cancer.Type: GrantFiled: December 28, 2000Date of Patent: October 24, 2006Assignee: Bioniche Life Sciences Inc.Inventors: Mario C. Filion, Nigel C. Phillips
-
Patent number: 7122195Abstract: This invention relates to recA mutant mycobacteria, particularly mutants of mycobacterial species which are members of the Mycobacterium tuberculosis complex, such as M. bovis BCG and M. tuberculosis. These mutant mycobacteria are useful as immunotherapteutic agents and vaccines for the treatment of a range of disorders, including tuberculosis.Type: GrantFiled: December 18, 2001Date of Patent: October 17, 2006Inventors: Kay Colston, legal representative, Eric Boettger, Peter Sander, Burkhard Springer, Jo Colston, deceased
-
Patent number: 7101701Abstract: Provided is a method for culturing Mycobacteria in the presence of a class A lantibiotic, thereby inhibiting or reducing bacterial contamination in the culture, without significantly disadvantageously affecting or retarding mycobacterial growth. Further provided are the Mycobacteria culture produced thereby, methods for detecting Mycobacteria in a biological sample under conditions that reduce bacterial contamination, and for diagnosing a mycobacterial infection in a biological sample from a subject suspected of having such an infection, as well as, kits useful in practicing such methods.Type: GrantFiled: October 7, 2005Date of Patent: September 5, 2006Assignee: The Trustees of the University of PennsylvaniaInventor: Robert H. Whitlock
-
Patent number: 7094403Abstract: The invention relates to Mycobacterium tuberculosis superoxide dismutase antibodies, methods of using them for detection of M. tuberculosis, methods of testing for an inhibitor of an M. tuberculosis superoxide dismutase, and methods of detecting tuberculosis infection.Type: GrantFiled: January 17, 2003Date of Patent: August 22, 2006Assignee: Yung Shin Pharmaceutical Ind. Co., Ltd.Inventors: Fang-Jen S. Lee, Chung-Hsiun H. Wu
-
Patent number: 7090980Abstract: A method of detecting a specific acid-fast bacterium, wherein primers having nucleotide sequences homologous or complementary to the specific regions in the rRNAs of the specific acid-fast bacterium are used to specifically amplify only the rRNAs of the specific acid-fast bacterium.Type: GrantFiled: December 18, 2003Date of Patent: August 15, 2006Assignee: Tosoh CorporationInventors: Noriyoshi Masuda, Yuichi Isawa, Ryuichi Horie, Kiyoshi Yasukawa
-
Patent number: 7074559Abstract: The present invention provides nucleic acid molecules unique to M. paratuberculosis. The invention also provides the polypeptides encoded by the M. paratuberculosis-specific nucleic acid molecules of the invention, and antibodies having specific binding affinity for the polypeptides encoded by the M. paratuberculosis-specific nucleic acid molecules. The invention further provides for methods of detecting M. paratuberculosis in a sample using nucleic acid molecules, polypeptides, and antibodies of the invention. The invention additionally provides methods of preventing a M. paratuberculosis infection in an animal.Type: GrantFiled: April 30, 2002Date of Patent: July 11, 2006Assignees: Refents of the University of Minnesota, The Unites States of America as represented by the Secretary of AgricultureInventors: Vivek Kapur, John P. Bannantine, Ling-Ling Li, Qing Zhang, Alongkorn Amonsin
-
Patent number: 7067136Abstract: This invention relates to a novel mycobacterial protein named DES, which appears to share significant amino acid sequence homology with soluble stearoyl-ACP desaturases. The results of allelic exchange experiments, indicate that the des gene may be essential to the survival of mycobacteria. These results coupled with the surface localization, the unique structure of DES, and the fact this antigen is expressed in vivo, and DES protein induces a humoral response in human patients, indicate that the DES protein provides a new target for the design of anti-mycobacterial drugs. This invention provides methods of screening molecules that can inhibit the DES enzyme activity of purified DES protein, in order to identify antibiotic molecules that are capable of inhibiting the growth or survival of mycobacteria.Type: GrantFiled: August 10, 2004Date of Patent: June 27, 2006Assignee: Institut PasteurInventors: Mary Jackson, Brigitte Gicquel
-
Patent number: 7056717Abstract: Genes have been isolated from Methylomonas 16a sp. encoding the isoprenoid biosynthetic pathway. The genes and gene products are the first isolated from a Methylomonas strain that is capable of utilizing single carbon (C1) substrates as energy sources. The genes and gene products of the present invention may be used in a variety of ways for the production of isoprenoid compounds in a variety of organisms.Type: GrantFiled: November 3, 2003Date of Patent: June 6, 2006Assignee: E. I. du Pont de Nemours and CompanyInventors: Qiong Cheng, Mattheos Koffas, Kelley C. Norton, James M. Odom, Stephen K. Picataggio, Andreas Schenzle, Jean-Francois Tomb, Pierre E. Rouviere
-
Patent number: 7037510Abstract: The present invention discloses fusion proteins of the immunodominant antigens ESAT-6 and Ag85B from Mycobacterium tuberculosis or homologues thereof, and a tuberculosis vaccine based on the fusion proteins, which vaccine induces efficient immunological memory.Type: GrantFiled: March 13, 2001Date of Patent: May 2, 2006Assignee: Statens Serum InstitutInventors: Peter Andersen, Anja Weinreich Olsen, Rikke Louise Vinther Skjøt, Peter Birk Rasmussen
-
Patent number: 7022320Abstract: Recombinant nucleic acid molecules are described. The molecules have a sequence or sequences encoding at least two M. tuberculosis antigens. Vectors and compositions containing these molecules are also described. In addition, compositions containing a cocktail of recombinant nucleic acid molecules having a sequence or sequences encoding one or more M. tuberculosis antigens are described. Methods of eliciting an immune response using these molecules and compositions are also described.Type: GrantFiled: February 9, 2000Date of Patent: April 4, 2006Assignee: PowderJect Vaccines, Inc.Inventors: Michael D. Macklin, Deborah L. Fuller
-
Patent number: 6982085Abstract: The present invention is based on the identification and characterization of a number of novel M. tuberculosis derived proteins and protein fragments. The invention is directed to the polypeptides and immunologically active fragments thereof, the genes encoding them, immunological compositions such as diagnostic reagents containing the polypeptides.Type: GrantFiled: May 2, 2002Date of Patent: January 3, 2006Assignee: Statens Serum InstitutInventors: Peter Andersen, Karin Weldingh, Christina Veggerby Hansen, Walter Florio, Li Mei Meng Okkels, Rikke Louise Vinther Skjot, Peter Birk Rasmussen
-
Patent number: 6979450Abstract: Methods and compositions for the detection and diagnosis of infectious diseases are provided. In particular, efficient and sensitive methods and compositions for the detection of active mycobacterial disease are provided for distinguishing between individuals having active disease, and individuals who have been immunologically exposed, such as those infected with a mycobacterium but are without active disease, or those who have been vaccinated with BCG. The methods comprise topical application of antigen compositions for transdermal delivery.Type: GrantFiled: June 6, 2001Date of Patent: December 27, 2005Assignee: Japan BCG LaboratoryInventor: Reiko M. Nakamura
-
Patent number: 6977075Abstract: The methods of the invention can be used to treat mycobacterial infections, or any disease or disorder that is caused by (or aggravated by) an intracellular pathogen. Accordingly, the invention features methods for treating a subject who has a disorder that is associated with an intracellular pathogen by administering, to a subject, a molecular conjugate that includes a photosensitizer (a term used herein to refer to a light activatable compound) and a targeting moiety, the targeting moiety being capable of targeting the conjugate to the intracellular pathogen.Type: GrantFiled: April 14, 2003Date of Patent: December 20, 2005Assignee: The General Hospital CorporationInventors: Tayyaba Hasan, Jerome Gross, Gerard J. Nau
-
Patent number: 6962710Abstract: Compounds and methods for inducing protective immunity against tuberculosis are disclosed. The compounds provided include polypeptides that contain at least one immunogenic portion of one or more M. tuberculosis proteins and DNA molecules encoding such polypeptides. Such compounds may be formulated into vaccines and/or pharmaceutical compositions for immunization against M. tuberculosis infection, or may be used for the diagnosis of tuberculosis.Type: GrantFiled: February 25, 2002Date of Patent: November 8, 2005Assignee: Corixa CorporationInventors: Steven G. Reed, Yasir A. W. Skeiky, Davin C. Dillon, Antonio Campos-Neto, Raymond Houghton, Thomas S. Vedvick, Daniel R. Twardzik, Michael J. Lodes, Ronald C. Hendrickson
-
Patent number: RE39494Abstract: The invention relates to a method for making an inactivated vaccine of Mycoplasma hyopneumoniae by inactivating the bacteria with Thimerosal. The resulting bacterin is mixed with an adjuvant of aluminum hydroxide and DEAE dextran and injected into pigs. The resulting bacterin and adjuvant mixture can also be mixed with other bacteria such as Bordetella and Pasteurella, for further adjuvant effect. Protective immunity against mycoplasmal pneumonia is elicited in swine using these vaccines.Type: GrantFiled: August 5, 2004Date of Patent: February 27, 2007Assignee: Intervet Inc.Inventors: Gerald R. Fitzgerald, C. Joseph Welter